We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
- Authors
Lash, T L; Pedersen, L; Cronin-Fenton, D; Ahern, T P; Rosenberg, C L; Lunetta, K L; Silliman, R A; Hamilton-Dutoit, S; Garne, J P; Ewertz, M; Sørensen, H T; Sørensen, H T
- Abstract
Tamoxifen remains an important adjuvant therapy to reduce the rate of breast cancer recurrence among patients with oestrogen-receptor-positive tumours. Cytochrome P-450 2D6 metabolizes tamoxifen to metabolites that more readily bind the oestrogen receptor. This enzyme also metabolizes selective serotonin reuptake inhibitors (SSRI), so these widely used drugs - when taken concurrently - may reduce tamoxifen's prevention of breast cancer recurrence. We studied citalopram use in 184 cases of breast cancer recurrence and 184 matched controls without recurrence after equivalent follow-up. Cases and controls were nested in a population of female residents of Northern Denmark with stages I-III oestrogen-receptor-positive breast cancer 1985-2001 and who took tamoxifen for 1, 2, or most often for 5 years. We ascertained prescription histories by linking participants' central personal registry numbers to prescription databases from the National Health Service. Seventeen cases (9%) and 21 controls (11%) received at least one prescription for the SSRI citalopram while taking tamoxifen (adjusted conditional odds ratio=0.85, 95% confidence interval=0.42, 1.7). We also observed no reduction of tamoxifen effectiveness among regular citalopram users (>or=30% overlap with tamoxifen use). These results suggest that concurrent use of citalopram does not reduce tamoxifen's prevention of breast cancer recurrence.
- Subjects
TAMOXIFEN; BREAST cancer; DRUG efficacy; CANCER relapse; ANTINEOPLASTIC agents; SEROTONIN uptake inhibitors; CITALOPRAM; BREAST tumors; COMBINATION drug therapy; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; RESEARCH; RESEARCH funding; SURVIVAL; TUMOR classification; EVALUATION research; TREATMENT effectiveness; CASE-control method; DIAGNOSIS; THERAPEUTICS; PREVENTION
- Publication
British Journal of Cancer, 2008, Vol 99, Issue 4, p616
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6604533